US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alcobra

10.22

0.0000

Volume:- -

Turnover:- -

Market Cap:281.69M

PE:-11.48

High:10.22

Open:10.22

Low:10.22

Close:10.22

Loading ...

Overview Company News Filings

The 7 things that make ADHD much worse

The Australian Financial Review

My boyfriend has ADHD, $50,000 in student-loan debt and no plan to pay it off. Is it my responsibility to step in and help?

Menopause in the workplace: Is your company doing enough to support you through this transition?

I’ve always worked too hard. It took an ADHD diagnosis and a breakdown to change that

The Sydney Morning Herald

Rise in youth gaming addiction due to more enticing games and smart devices, say counsellors

Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD

Arthur Hayes's 2028 Prediction: Bitcoin To Hit One Million, Altcoins To Shed Blood

Press Release: Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

ACCESS Newswire

She teaches parkour to empower women and kids – and change the public’s perceptions about the sport

Hefei Lifeon Pharmaceutical Gets Drug Registration for ADHD Tablets; Shares Soar 10%

MT Newswires Live

ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million

Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301

Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

Buy Rating Affirmed for Axsome Therapeutics Amid Promising ADHD Treatment Results and Strategic Market Positioning

Axsome Therapeutics' Phase 3 Trial of Solriamfetol to Treat ADHD Meets Primary Endpoint

MT Newswires Live

Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ADHD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ADHD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADHD\",,,,,undefined,":{"symbol":"ADHD","market":"US","secType":"STK","nameCN":"Alcobra","latestPrice":10.22,"timestamp":1510952400000,"preClose":10.22,"halted":4,"volume":0,"delay":0,"floatShares":8881019,"shares":27563000,"eps":-0.89,"marketStatus":"Delisted","change":0,"latestTime":"11-17 16:00:00 EST","open":10.22,"high":10.22,"low":10.22,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.89,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":10.22,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ADHD\",,,,,undefined,":{"symbol":"ADHD","floatShares":8881019,"roa":"--","roe":"--","lyrEps":0,"shares":27563000,"dividePrice":0,"high":10.22,"amplitude":0,"preClose":10.22,"low":10.22,"week52Low":5.8113,"pbRate":"5.96","week52High":18.0414,"institutionHeld":0,"latestPrice":10.22,"eps":-0.89,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.89,"open":10.22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ADHD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546768047","title":"The 7 things that make ADHD much worse","url":"https://stock-news.laohu8.com/highlight/detail?id=2546768047","media":"The Australian Financial Review","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546768047?lang=en_us&edition=fundamental","pubTime":"2025-06-27 07:22","pubTimestamp":1750980120,"startTime":"0","endTime":"0","summary":"From forgotten appointments and lost keys to emotional volatility, poor sleep and chronic procrastination, living with attention-deficit/hyperactivity disorder can feel like being on a rollercoaster w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.afr.com/life-and-luxury/health-and-wellness/poor-sleep-and-no-routine-the-7-things-that-make-adhd-worse-20250626-p5manb","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"afr_stock","symbols":["BK4139","ADHD","ABVC"],"gpt_icon":0},{"id":"2546678606","title":"My boyfriend has ADHD, $50,000 in student-loan debt and no plan to pay it off. Is it my responsibility to step in and help?","url":"https://stock-news.laohu8.com/highlight/detail?id=2546678606","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546678606?lang=en_us&edition=fundamental","pubTime":"2025-06-26 18:00","pubTimestamp":1750932000,"startTime":"0","endTime":"0","summary":"MW My boyfriend has ADHD, $50,000 in student-loan debt and no plan to pay it off. Is it my responsibility to step in and help?'He works a full-time job, pays bills on time and is a genuinely good person, but I feel like he's just living day by day'. I  live with my boyfriend . He works a full-time job, pays bills on time and is a genuinely good person, but I feel like he's just living day by day and not really thinking about his financial future.He has never owned a credit card and has racked up considerable student-loan debt after earning two degrees. He hasn't defaulted or anything - I know he stopped making payments when the government paused repayment, but I believe he is up to date on them. He and I are both bad about ordering from DoorDash  out of convenience when we could easily cook or pick up food on our block. That's probably the most irresponsible spending he does. He's otherwise good with saving!However, I think it's important to remember that you both are so young. Having ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4549","BK4536","BK4503","BK4122","BK4551","BK4548","LU2065171311.SGD","LU2065170008.USD","BK4535","BK4139","BK4588","BK4585","LU2065171402.SGD","LU2065169927.USD","BK4505","ABVC","BK4209","DASH","ADHD"],"gpt_icon":0},{"id":"2545467253","title":"Menopause in the workplace: Is your company doing enough to support you through this transition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2545467253","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545467253?lang=en_us&edition=fundamental","pubTime":"2025-06-23 07:17","pubTimestamp":1750634245,"startTime":"0","endTime":"0","summary":"A recent White Paper revealed that over 70 per cent of female employees in Singapore think a menopause-friendly policy would benefit their organisation. But the number of companies offering this support is low. CNA Women finds out why this isn’t just a women’s issue, but good business.","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s--WTriwNMA--/c_crop,h_1299,w_1732,x_304,y_1/c_fill,g_auto,h_622,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/06/06/managing_menopause_at_work.jpg?itok=hnD7oQ_n","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--WTriwNMA--/c_crop,h_1299,w_1732,x_304,y_1/c_fill,g_auto,h_622,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/06/06/managing_menopause_at_work.jpg?itok=hnD7oQ_n"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/women/menopause-support-work-singapore-5169011","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["BK4212","BK4588","5GC.SI","ADHD","BK4585","CALM"],"gpt_icon":0},{"id":"2544969302","title":"I’ve always worked too hard. It took an ADHD diagnosis and a breakdown to change that","url":"https://stock-news.laohu8.com/highlight/detail?id=2544969302","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544969302?lang=en_us&edition=fundamental","pubTime":"2025-06-17 17:30","pubTimestamp":1750152600,"startTime":"0","endTime":"0","summary":"I’m about to share something I’m afraid I’ll regret. That I’ll limit my professional opportunities by sharing what sometimes goes on in my brain. But, at a time when study after study tells us our col","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/workplace/i-ve-always-worked-too-hard-it-took-an-adhd-diagnosis-and-a-breakdown-to-change-that-20250617-p5m82q.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["ADHD","ABVC"],"gpt_icon":0},{"id":"2544012931","title":"Rise in youth gaming addiction due to more enticing games and smart devices, say counsellors","url":"https://stock-news.laohu8.com/highlight/detail?id=2544012931","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544012931?lang=en_us&edition=fundamental","pubTime":"2025-06-17 11:39","pubTimestamp":1750131564,"startTime":"0","endTime":"0","summary":"Therapists noted a 30 per cent increase in gaming addiction cases since the COVID-19 pandemic, adding that youths make up most of the cases.","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--s2QkauJa--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/06/17/screenshot_2025-06-17_101733.png?itok=2qHymOxE","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--s2QkauJa--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_mediacorp:cna:watermark:2021-08:cna,w_0.1/f_auto,q_auto/v1/mediacorp/cna/image/2025/06/17/screenshot_2025-06-17_101733.png?itok=2qHymOxE"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/gaming-addiction-mental-health-youths-singapore-5186216","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["ADHD"],"gpt_icon":0},{"id":"2536061796","title":"Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2536061796","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536061796?lang=en_us&edition=fundamental","pubTime":"2025-05-20 20:00","pubTimestamp":1747742400,"startTime":"0","endTime":"0","summary":"Subjects Demonstrated Marked Improvement of ADHD Symptoms at Week 5New Drug Application on Schedule for this Summer CING CEO Shares Insights and Strategic Outlook on “Unboxing Biotech” Podcast  KANSAS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/05/20/3084809/0/en/Efficacy-Results-Announced-from-Cingulate-s-Phase-3-Pediatric-Study-of-CTx-1301-dexmethylphenidate-for-ADHD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CING","ITT","ADHD","LU0053671581.USD","BK4139","ABVC","BK4007","LU0054578231.USD","BK4161"],"gpt_icon":0},{"id":"2535902330","title":"Arthur Hayes's 2028 Prediction: Bitcoin To Hit One Million, Altcoins To Shed Blood","url":"https://stock-news.laohu8.com/highlight/detail?id=2535902330","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535902330?lang=en_us&edition=fundamental","pubTime":"2025-05-16 14:04","pubTimestamp":1747375440,"startTime":"0","endTime":"0","summary":"Original Title: Fatty Fatty Boom BoomOriginal Author: Arthur HayesOriginal Translator: DeepTech TechFlowSurprisingly, there are many similarities between the advocate of \"Fat Acceptance,\" singer Lizzo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info/en/news/58201","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_highlight","symbols":["CIO","BK4588","MBS","BK4194","BK4223","BK4594","BK4585","BTC.USD.HKCC","BK4601","ADHD","BK4581","BTC.USD.CC"],"gpt_icon":1},{"id":"2533683350","title":"Press Release: Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2533683350","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533683350?lang=en_us&edition=fundamental","pubTime":"2025-05-06 18:45","pubTimestamp":1746528300,"startTime":"0","endTime":"0","summary":"Delivers First Quarter Net Sales of $419.9 Million, Reflecting a 10%Year-Over-Year Decrease on a Reported Basis; Excluding Impact of Therakos  Divestiture, Net Sales Grew 2.5%. Reports Net Loss of $27.7 Million and Adjusted EBITDA of $102.3 Million. Acthar Gel  Net Sales Increased 12.3%, Representing Fifth Consecutive Quarter of Growth. INOmax EVOLVE DS Delivery System Now in More Than 50 Hospitals Nationwide. DUBLIN, May 6, 2025 /PRNewswire/ -- Mallinckrodt plc , a global specialty pharmaceutical company, today reported its financial results for the first quarter ended March 28, 2025.Mallinckrodt's net sales in the first quarter of 2025 were $419.9 million, as compared to $467.8 million in the first quarter of 2024. This reflects a 10.2% decrease on a reported and constant currency basis. Excluding the impact of the Therakos divestiture, total net sales grew by 2.5%.The Company's Specialty Brands segment reported net sales of $207.3 million, as compared to $257.3 million in the first ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["API","BK4585","BK4588","BK4604","BK4232","BK4555","ADHD","BK4503","BK4551","BK4007","03160","BK4535","MNK","R","TM","BK4099","BK4023","BK4022"],"gpt_icon":0},{"id":"2533553538","title":"Axsome Therapeutics Clocks Around 60% Topline Growth In Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2533553538","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533553538?lang=en_us&edition=fundamental","pubTime":"2025-05-05 22:41","pubTimestamp":1746456109,"startTime":"0","endTime":"0","summary":"Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo&#39;s U.S. launch and advances key drug programs.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/05/45196924/neurology-focused-axsome-therapeutics-clocks-around-60-topline-growth-in-q1-commercial-availability-of-newly-approved-migraine-drug-expected-in-june","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADHD","BK4505","AXSM","BK4585","BK4007"],"gpt_icon":0},{"id":"2531776052","title":"Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2531776052","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531776052?lang=en_us&edition=fundamental","pubTime":"2025-04-30 23:15","pubTimestamp":1746026142,"startTime":"0","endTime":"0","summary":"Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on Cingulate Inc (CING – Research Report). The associated price target remains t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cingulate-inc-receives-buy-rating-amid-promising-developments-in-adhd-treatment-ctx-1301?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cingulate-inc-receives-buy-rating-amid-promising-developments-in-adhd-treatment-ctx-1301?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","CING","ADHD"],"gpt_icon":0},{"id":"2531733589","title":"Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2531733589","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531733589?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food. CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD. The trial demonstrated that 50mg CTx-1301 can be taken with or without food. Multiple pharmacokinetic  measurements were taken, and adverse events were consistent with previous findings and indicate a favorable tolerability profile.“Similar to the 25mg fasted versus fed study conducted with CTx-1301 , the 50mg dose of CTx-1301 demonstrated that it may also be taken with or without food, however patients should be advised to take the medication consistently as such,\" said Raul Silva, MD, Chief Science Officer, Cingulate. “Most importantly is that the unique formulation of CTx-1301 is bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cingulate-announces-positive-top-line-120000878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","IE00B5TLWC47.USD","CINGW","BK4104","US5Y.BOND","US10Y.BOND","ADHD","BK4181","BK4139","BK4585","US7Y.BOND","PK","CING","BK4007","FAST","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","US2Y.BOND","US3Y.BOND","US30Y.BOND","ABVC","BK4567","BK4588","US6M.BOND","US12M.BOND"],"gpt_icon":0},{"id":"2529842356","title":"Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529842356","media":"ACCESS Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529842356?lang=en_us&edition=fundamental","pubTime":"2025-04-22 04:05","pubTimestamp":1745265900,"startTime":"0","endTime":"0","summary":"DENVER, CO / ACCESS Newswire / April 21, 2025 / Aytu BioPharma,Inc.  , a pharmaceutical company focused on commercializing novel therapeutics, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 1:30 p.m. Pacific time . Josh Disbrow, CEO of Aytu, will be hosting the presentation and answering questions at the conclusion.Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub. Aytu is a pharmaceutical company focused on commercializing novel therapeutics. The Company's prescription products include Adzenys XR-ODT  extended-release orally disintegrating tablets  and Cotempla XR-ODT  extended-release orally disintegrating tablets  for the treatment of attention deficit hyperactivity disorder , Karbinal ER , an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescripti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aytu-biopharma-present-planet-microcap-200500253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AYTU","BK4007","ADHD"],"gpt_icon":0},{"id":"2528904603","title":"She teaches parkour to empower women and kids – and change the public’s perceptions about the sport","url":"https://stock-news.laohu8.com/highlight/detail?id=2528904603","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528904603?lang=en_us&edition=fundamental","pubTime":"2025-04-19 07:07","pubTimestamp":1745017651,"startTime":"0","endTime":"0","summary":"Growing up, Gwendolyn Neo was told not to jump or climb, even though boys were allowed to. The co-founder of Lion City Parkour wants to restore a sense of freedom to women and children through the sport, while rallying female practitioners through her Women of Parkour Singapore interest group.","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s--0HW5SUDm--/c_crop,h_720,w_960,x_5,y_0/c_fill,g_auto,h_622,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/04/08/gwendolyn_neo-co-founder_of_lion_city_parkour_and_women_of_parkour.jpg?itok=spEWvDTi","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--0HW5SUDm--/c_crop,h_720,w_960,x_5,y_0/c_fill,g_auto,h_622,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/04/08/gwendolyn_neo-co-founder_of_lion_city_parkour_and_women_of_parkour.jpg?itok=spEWvDTi"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/women/women-parkour-community-gwendolyn-neo-lion-city-parkour-founder-5051576","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["LU1564329032.USD","ADHD","LU2065171402.SGD","LU1732799900.SGD","LU0672654240.SGD","LU1642822529.SGD","LU2756315318.SGD","LU1868836757.USD","LU1868836914.USD","LU1548497426.USD","IE00BFSS7M15.SGD","LU0082616367.USD","LU0106261372.USD","LU0882574139.USD","LU2430703095.HKD","LU0553294199.USD","LU2236285917.USD","SG9999002224.SGD","LU0964807845.USD","LU0320765059.SGD","LU2065169927.USD","LU1119994496.HKD","LU0795875086.SGD","LU1629891620.HKD","LU2250418816.HKD","LU2360106780.USD","LU2361044865.SGD","LU2023250330.USD","IE00B1XK9C88.USD","LU0267386448.USD","LU0878866978.SGD","LU1366333091.USD","5GC.SI","LU2463028550.USD","LU2552382215.SGD","SG9999015978.USD","IE0004445239.USD","LU0345769631.USD","IE0002270589.USD","LU2764262908.HKD","LU2381873111.SGD","SG9999015986.USD","SG9999017495.SGD","IE00BJJMRX11.SGD","LU0154236417.USD","LU1280957306.USD","LU1697837992.HKD","LU1861558580.USD","LU1064131342.USD"],"gpt_icon":1},{"id":"2527843036","title":"Hefei Lifeon Pharmaceutical Gets Drug Registration for ADHD Tablets; Shares Soar 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2527843036","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527843036?lang=en_us&edition=fundamental","pubTime":"2025-04-15 14:35","pubTimestamp":1744698915,"startTime":"0","endTime":"0","summary":"Hefei Lifeon Pharmaceutical  obtained drug registration from China's drug administrator for its methylphenidate hydrochloride extended-release tablets.The drug is a first-class psychotropic substance mainly used to treat attention deficit hyperactivity disorder, according to a Tuesday filing with the Shenzhen bourse.Shares of the pharmaceutical company rose 10% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABVC","BK0250","003020","BK4139","ADHD"],"gpt_icon":0},{"id":"2524693257","title":"ABVC's Subsidiary AiBtl Signs Share-for-Land Agreement in Asia With Deal Valued at USD $7.67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2524693257","media":"NewMediaWire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524693257?lang=en_us&edition=fundamental","pubTime":"2025-04-03 21:00","pubTimestamp":1743685200,"startTime":"0","endTime":"0","summary":"The acquired land will be designated for the cultivation and extraction of Polygala tenuifolia , a central ingredient in AiBtl's botanical drug candidates for Major Depressive Disorder  and Attention Deficit Hyperactivity Disorder . The Company believes this move is key to reducing sourcing risk and supporting large-scale, high-quality production of active botanical compounds.\"This agreement is a long-term investment into securing the future of botanical drug innovation,\" said Uttam Patil, Ph.D., Chief Executive Officer of ABVC. \"By locking in upstream resources in Asia, we are strengthening AiBtl's infrastructure from seed to formulation - giving our neuroscience pipeline a sustainable foundation.\". The transaction also reflects ABVC's continuing efforts to expand its physical and operational footprint in the Asia-Pacific region while enhancing value for global shareholders.ADHD Drug Candidate: The ADHD market is expected to exceed $24 billion by 2032, fueled by increasing diagnoses a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abvcs-subsidiary-aibtl-signs-share-130000720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4232","BK4022","ABVC","USD","ADHD","R","BK4139"],"gpt_icon":0},{"id":"2524184251","title":"Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2524184251","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524184251?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"“Our meeting with the FDA yesterday was very productive, and we remain on track for an NDA filing of CTx-1301 in mid-2025. We truly appreciate the FDA personnel who have been involved with the regulatory review of CTx-1301 to date. These interactions have been essential in helping us generate data to demonstrate the consistency and therapeutic benefit of our product. This important milestone is validation of our mission to bring to market the first, true, once-daily stimulant medication to treat ADHD over the entire active day,” said Cingulate Chairman and CEO Shane J Schaffer.About CTx-1301Cingulate’s lead candidate, CTx-1301, utilizes Cingulate’s proprietary PTR drug delivery platform to create a breakthrough, multi-core formulation of the active pharmaceutical ingredient dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD. Dexmethylphenidate is part of the stimulant class of medicines and increases norepinephrine and dopamine activity in the brain to affect ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cingulate-completes-pre-nda-meeting-120000674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ADHD","ABVC","CING","CINGW","BK4007"],"gpt_icon":0},{"id":"2524619454","title":"Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524619454","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524619454?lang=en_us&edition=fundamental","pubTime":"2025-04-01 19:00","pubTimestamp":1743505200,"startTime":"0","endTime":"0","summary":"Results support continued development in MDD with concomitant EDS; Phase 3 trial planned in 2025 Approximately 50 percent of MDD patients experience EDS1, highlighting high unmet need NEW YORK, April ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3053170/33090/en/Axsome-Therapeutics-Announces-Topline-Results-of-PARADIGM-Phase-3-Proof-of-Concept-Trial-of-Solriamfetol-in-Major-Depressive-Disorder-MDD-with-and-without-Excessive-Daytime-Sleepin.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PACI.U","BK4139","ABVC","BK4215","ESS","BK4505","ADHD","BK4597","AXSM","BK4135","BK4585","BK4588","CNS","BK4007"],"gpt_icon":0},{"id":"2522845871","title":"Buy Rating Affirmed for Axsome Therapeutics Amid Promising ADHD Treatment Results and Strategic Market Positioning","url":"https://stock-news.laohu8.com/highlight/detail?id=2522845871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522845871?lang=en_us&edition=fundamental","pubTime":"2025-03-26 16:35","pubTimestamp":1742978128,"startTime":"0","endTime":"0","summary":"Analyst Jason Gerberry from Bank of America Securities maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) and increased the pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-axsome-therapeutics-amid-promising-adhd-treatment-results-and-strategic-market-positioning?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-affirmed-for-axsome-therapeutics-amid-promising-adhd-treatment-results-and-strategic-market-positioning?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADHD","ABVC","AXSM"],"gpt_icon":0},{"id":"2522021437","title":"Axsome Therapeutics' Phase 3 Trial of Solriamfetol to Treat ADHD Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2522021437","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522021437?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:45","pubTimestamp":1742903124,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics  said Tuesday that the phase 3 trial of solriamfetol as a potential treatment for attention deficit hyperactivity disorder achieved its primary and key secondary endpoints, demonstrating \"statistically significant\" improvement in symptoms and disease severity.The study met its primary endpoint of a statistically significant reduction in the Adult ADHD Investigator Symptom Rating Scale compared with placebo at week six. The study also achieved the key secondary endpoint of a significant reduction in overall ADHD disease severity, Axsome added.Solriamfetol was also well-tolerated in the study, with no serious adverse events reported, according to Axsome.Axsome Chief Executive Officer Herriot Tabuteau said the company plans to start a solriamfetol trial in pediatric patients this year.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","ADHD","BK4505","BK4585","ABVC","BK4139","AXSM"],"gpt_icon":0},{"id":"2519633827","title":"Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2519633827","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519633827?lang=en_us&edition=fundamental","pubTime":"2025-03-14 22:55","pubTimestamp":1741964100,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics’ AXSM Auvelity  was launched in the United States in 2022 for the treatment of major depressive disorder , making it the first approved drug in the company’s portfolio.Auvelity generated sales worth $291.4 million in 2024, reflecting an increase of 124% year over year in the United States. Sales of the drug are being driven by an increase in unit sales volume and the momentum is likely to continue in 2025.Axsome is also working to expand the label of Auvelity for the larger commercial opportunity in other central nervous system  disorders like Alzheimer’s disease  agitation and smoking cessation.The successful development and potential approval of Auvelity in additional indications will help the drug address a broader patient population and drive sales further.Axsome is evaluating Sunosi in separate phase III studies for treating attention deficit hyperactivity disorder , MDD, binge eating disorder and excessive sleepiness associated with shift work disorder.Top-lin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/auvelity-other-drugs-aid-axsms-145500596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171402.SGD","LU0889565916.HKD","BK4585","ACAD","BK4007","BK4533","JAZZ","LU2065170008.USD","LU0109394709.USD","CNS","BK4532","IE00BN0W2T93.GBP","LU0320765992.SGD","IE00BN0W2V16.EUR","BK4505","BK4135","LU2065169927.USD","LU2065171311.SGD","AXSM","BK4139","ABVC","ADHD","LU0823416689.USD","IE00BN0W2W23.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ADHD\",params:#limit:5,,,undefined,":[{"date":"2017-11-16","symbol":"ADHD","newSymbol":"ARCT","type":"symbolChange","dateTimestamp":1510808400000},{"date":"2017-11-15","symbol":"ADHD","type":"split","dateTimestamp":1510722000000,"forFactor":7,"toFactor":1},{"market":"US","date":"2017-11-09","symbol":"ADHD","fiscalQuarterEnding":"2017/09","expectedEps":-0.08,"name":null,"time":"","type":"earning","dateTimestamp":1510203600000,"reportTimeType":"","actualEps":-0.09},{"market":"US","date":"2017-08-11","symbol":"ADHD","fiscalQuarterEnding":"2017/06","expectedEps":-0.13,"name":null,"time":"","type":"earning","dateTimestamp":1502424000000,"reportTimeType":"","actualEps":-0.13},{"market":"US","date":"2017-05-30","symbol":"ADHD","fiscalQuarterEnding":"2017/03","expectedEps":-0.2,"name":null,"time":"","type":"earning","dateTimestamp":1496116800000,"reportTimeType":"","actualEps":-0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ADHD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ADHD\",market:\"US\",delay:false,,,undefined,":{}}}